# A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

> clinical trial · VERIFIED · 2026-07-29

Status: RECRUITING · Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Condition: Lymphoma

- Company: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07015242

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.